Symptomatic Aseptic Sinusitis Induced by Immune Checkpoint Inhibitors for Metastatic Melanoma Treatment

Overview

Journal Immunotherapy

Specialties Allergy & Immunology
Pharmacology

Date 2024 Sep 13

PMID 39268924

Authors

Sofia Tzoumpa

Beatrice Villette

Florence Granel-Brocard

Caroline Dutriaux

Alexandre Memmi

Geraldine Jeudy

Victor Tafani

Melanie Saint-Jean

Charlee Nardin

Elisa Funck-Brentano

Yannick Le Corre

Gaelle Quereux

Eve Maubec

Affiliations

Soon will be listed here.

Abstract

Immune-mediated sinusitis is poorly described and may easily go undiagnosed. We conducted a retrospective, multicenter, national study focusing on symptomatic immune-mediated sinusitis in patients receiving immune checkpoint inhibitors (ICIs) for melanoma treatment. Twelve patients were included (50% women, median age 58 years). Overall, the paraclinical assessment, the inefficacy of antibiotic/antihistaminic treatment, the improvement of symptoms on immunosuppressants and/or after ICI discontinuation, and the presence of multiple concomitant immune-related adverse-events, suggested a noninfectious etiology. Recognizing this toxicity is imperative for limitation of diagnostic wandering and appropriate treatment. However, additional epidemiological studies are needed to assess its prevalence as a potential immune-related adverse-event, and its prognostic value in patients treated with ICIs.

References

Krane N, Beswick D, Sauer D, Detwiller K, Shindo M . Allergic Fungal Sinusitis Imitating an Aggressive Skull Base Lesion in the Setting of Pembrolizumab Immunotherapy. Ann Otol Rhinol Laryngol. 2020; 130(1):108-111. DOI: 10.1177/0003489420937728. View

Rogado J, Sanchez-Torres J, Romero-Laorden N, Ballesteros A, Pacheco-Barcia V, Ramos-Levi A . Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer. 2019; 109:21-27. DOI: 10.1016/j.ejca.2018.10.014. View

Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts E . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30(2):239-45. DOI: 10.1038/clpt.1981.154. View

Machado A, Ratliff H, Abdelwahab A, Vohra M, Kuang A, Shatila M . The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review. J Cancer. 2023; 14(16):2956-2963. PMC: 10583582. DOI: 10.7150/jca.87335. View

Verheijden R, van Eijs M, May A, van Wijk F, Suijkerbuijk K . Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ Precis Oncol. 2023; 7(1):41. PMC: 10182067. DOI: 10.1038/s41698-023-00380-1. View

Standiford T, Patel N, Singh A, Gochman G, Jamie Wu T, Daud A . Pembrolizumab-associated chronic rhinosinusitis: A new endotype and management considerations. Int Forum Allergy Rhinol. 2023; 13(12):2248-2251. DOI: 10.1002/alr.23213. View

Brown V, Antol D, Racsa P, Ward M, Naidoo J . Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis. Cancer Invest. 2021; 39(10):789-796. DOI: 10.1080/07357907.2021.1913502. View

Robson J, Grayson P, Ponte C, Suppiah R, Craven A, Judge A . 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis Rheumatol. 2022; 74(3):393-399. DOI: 10.1002/art.41986. View

Postow M, Sidlow R, Hellmann M . Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018; 378(2):158-168. DOI: 10.1056/NEJMra1703481. View

10.

Maher V, Fernandes L, Weinstock C, Tang S, Agarwal S, Brave M . Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. J Clin Oncol. 2019; 37(30):2730-2737. DOI: 10.1200/JCO.19.00318. View

11.

Hammers H, Plimack E, Infante J, Rini B, Mcdermott D, Lewis L . Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. J Clin Oncol. 2017; 35(34):3851-3858. PMC: 7587408. DOI: 10.1200/JCO.2016.72.1985. View

12.

Dein E, Sharfman W, Kim J, Gellad F, Shah A, Bingham 3rd C . Two Cases of Sinusitis Induced by Immune Checkpoint Inhibition. J Immunother. 2017; 40(8):312-314. PMC: 5593775. DOI: 10.1097/CJI.0000000000000174. View

13.

Kassem F, Rosman Y, Blau I, Nageris B, Zakharov A, Biadsee A . Nivolumab-induced diffuse type 2 rhinosinusitis: A case report. Asian Pac J Allergy Immunol. 2021; . DOI: 10.12932/AP-240721-1196. View

14.

Das S, Johnson D . Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019; 7(1):306. PMC: 6858629. DOI: 10.1186/s40425-019-0805-8. View

15.

Carlino M, Larkin J, Long G . Immune checkpoint inhibitors in melanoma. Lancet. 2021; 398(10304):1002-1014. DOI: 10.1016/S0140-6736(21)01206-X. View

16.

Wang D, Salem J, Cohen J, Chandra S, Menzer C, Ye F . Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018; 4(12):1721-1728. PMC: 6440712. DOI: 10.1001/jamaoncol.2018.3923. View

17.

Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F . Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol. 2018; 145(2):511-521. DOI: 10.1007/s00432-018-2819-x. View

18.

Lozano A, Chaudhuri A, Nene A, Bacchiocchi A, Earland N, Vesely M . T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat Med. 2022; 28(2):353-362. PMC: 8866214. DOI: 10.1038/s41591-021-01623-z. View

19.

Ross C, Makhzoum J, Pagnoux C . Updates in ANCA-associated vasculitis. Eur J Rheumatol. 2022; 9(3):153-166. DOI: 10.5152/eujrheum.2022.20248. View